The metabolic cooperation between cells in solid cancer tumors

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 216-225

  Icard, Philippe ^a,b   Kafara, Perrine ^b,c,d   Steyaert, Jean Marc ^a   Schwartz, Laurent ^a   Lincet, Hubert ^b,c,d  

^a ÉCOLE POLYTECHNIQUE   (France)

^b Biologie des Thérapies Innovantes des Cancers Localement Agressifs BioTICLA EA 4656   (France)

^c NORMANDIE UNIVERSITÉ   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Autophagy; Tumoral metabolism; Tumoral microenvironment; Warburg effect; Waste products

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE; GLUCOSE; GLUTAMINE; LACTIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; NUCLEOTIDE; OXYGEN; POLYAMINE; PROTON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; FATTY ACID; LIPID; REACTIVE OXYGEN METABOLITE;

ADIPOCYTE; ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CELL FUNCTION; CELL INVASION; CELL PROLIFERATION; CITRIC ACID CYCLE; CONCENTRATION (PARAMETERS); ENERGY YIELD; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FATTY ACID SYNTHESIS; FIBROBLAST; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPOXIC CELL; IMMUNE RESPONSE; LIPOGENESIS; METABOLISM; NONHUMAN; NUTRIENT AVAILABILITY; OXIDATION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STROMA CELL; TUMOR MICROENVIRONMENT; ACIDIFICATION; ADAPTATION; CELL DIVISION; CELL HYPOXIA; CELL METABOLISM; CELLULAR IMMUNITY; GLUCONEOGENESIS; METASTASIS; OXIDATIVE PHOSPHORYLATION; POLYAMINE SYNTHESIS; TUMOR GROWTH; TUMOR IMMUNITY; WASTE;

AUTOPHAGY; TUMORAL METABOLISM; TUMORAL MICROENVIRONMENT; WARBURG EFFECT; WASTE PRODUCTS;

ADIPOCYTES; ANIMALS; CELL PROLIFERATION; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; OXYGEN; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84905247588     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.06.002     Document Type: Review

References (188)

1. Bertout J.A., Patel S.A., Simon M.C. The impact of O2 availability on human cancer. Nat. Rev. Cancer 2008, 8:967-975.
2. Keith B., Johnson R.S., Simon M.C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22.
3. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
4. Semenza G.L., Jiang B.H., Leung S.W., Passantino R., Concordet J.P., Maire P., Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271:32529-32537.
5. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
6. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.I., De Marzo A.M., Van Eyk J.E., Mendell J.T., Dang C.V. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
7. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
8. Olovnikov I.A., Kravchenko J.E., Chumakov P.M. Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin. Cancer Biol. 2009, 19:32-41.
9. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
10. Jang M., Kim S.S., Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp. Mol. Med. 2013, 45:e45. 10.1038/emm.2013.85.
11. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
12. Koshiji M., Kageyama Y., Pete E.A., Horikawa I., Barrett J.C., Huang L.E. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 2004, 23:1949-1956.
13. Moreno-Sanchez R., Rodriguez-Enriquez S., Marin-Hernandez A., Saavedra E. Energy metabolism in tumor cells. FEBS J. 2007, 274:1393-1418.
14. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26:225-239.
15. Barachal A.L., Bickerman H.A. The effect of anoxia on tumor growth with special reference to sarcoma 180 implanted in C57 mice. Cancer Res. 1954, 14:672-676.
16. Guppy M. The hypoxic core: a possible answer to the cancer paradox. Biochem. Biophys. Res. Commun. 2002, 299:676-680.
17. Masson N., Ratcliffe P.J. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2014, 2:3.
18. Parks S.K., Chiche J., Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 2013, 13:611-623.
19. Ratcliffe P.J. Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer. J. Physiol. 2013, 591:2027-2042.
20. Yuan J., Narayanan L., Rockwell S., Glazer P.M. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res. 2000, 60:4372-4376.
21. Bindra R.S., Crosby M.E., Glazer P.M. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 2007, 26:249-260.
22. Zhou Y., Tozzi F., Chen J., Fan F., Xia L., Wang J., Gao G., Zhang A., Xia X., Brasher H., Widger W., Ellis L.M., Weihua Z. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res. 2012, 72:304-314.
23. Rohwer N., Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat. 2011, 14:191-201.
24. Dvorak H.F., Weaver V.M., Tlsty T.D., Bergers G. Tumor microenvironment and progression. J. Surg. Oncol. 2011, 103:468-474.
25. Hensley C.T., Wasti A.T., Deberardinis R.J. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 2013, 123:3678-3684.
26. Deberardinis R.J., Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010, 29:313-324.
27. Eagle H., Oyama V.I., Levy M., Horton C.L., Fleischman R. The growth response of mammalian cells in tissue culture to L-glutamine and L-glutamic acid. J. Biol. Chem. 1956, 218:607-616.
28. Reitzer L.J., Wice B.M., Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 1979, 254:2669-2676.
29. Ko Y.H., Lin Z., Flomenberg N., Pestell R.G., Howell A., Sotgia F., Lisanti M.P., Martinez-Outschoorn U.E. Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: Implications for preventing chemotherapy resistance. Cancer Biol. Ther. 2011, 12.
30. Deberardinis R.J., Sayed N., Ditsworth D., Thompson C.B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 2008, 18:54-61.
31. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 2011, 43:969-980.
32. Wong N., De M.J., Tang D. PKM2, a central point of regulation in cancer metabolism. Int. J. Cell Biol. 2013, 2013. (242513, Epub@2013 Feb 14). 10.1155/2013/242513.
33. Wong N., Ojo D., Yan J., Tang D. PKM2 contributes to cancer metabolism. Cancer Lett. 2014, 10.
34. Mazurek S. Pyruvate kinase M2: a key enzyme of the tumor metabolome and its medical relevance. Biomed. Res. 2012, 23:133-141.
35. Israel M. Cancer: A Dysmethylation Syndrome 2005, John Libbey Eurotext.
36. Israel M. Four Hidden Metamorphoses: A Remark on Blood, Muscle, Mental Diseases and Cancer 2004, John Libbey Eurotext.
37. Mazurek S., Grimm H., Boschek C.B., Vaupel P., Eigenbrodt E. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br. J. Nutr. 2002, 87(Suppl. 1):S23-S29.
38. Medina M.A. Glutamine and cancer. J. Nutr. 2001, 131:2539S-2542S.
39. Barre B., Vigneron A., Perkins N., Roninson I.B., Gamelin E., Coqueret O. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol. Med. 2007, 13:4-11.
40. Barre B., Avril S., Coqueret O. Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J. Biol. Chem. 2003, 278:2990-2996.
41. Gao X., Wang H., Yang J.J., Liu X., Liu Z.R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012, 45:598-609.
42. WARBURG O., Wind F., Negelein E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8:519-530.
43. Lehninger A.L. Biochemistry, the Molecular Basis of Cell Structure and Function 1975, Worth Publishers, Inc.
44. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20:51-56.
45. Bayley J.P., Devilee P. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?. Curr. Opin. Genet. Dev. 2010, 20:324-329.
46. Pollard P.J., Briere J.J., Alam N.A., Barwell J., Barclay E., Wortham N.C., Hunt T., Mitchell M., Olpin S., Moat S.J., Hargreaves I.P., Heales S.J., Chung Y.L., Griffiths J.R., Dalgleish A., McGrath J.A., Gleeson M.J., Hodgson S.V., Poulsom R., Rustin P., Tomlinson I.P. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 2005, 14:2231-2239.
47. Giskeodegard G.F., Bertilsson H., Selnaes K.M., Wright A.J., Bathen T.F., Viset T., Halgunset J., Angelsen A., Gribbestad I.S., Tessem M.B. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS One 2013, 8:e62375.
48. Lincet H., Kafara P., Giffard F., Abeilard-Lemoisson E., Duval M., Louis M.H., Poulain L., Icard P. Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells. J. Ovarian Res. 2013, 6:72.
49. Lu Y., Zhang X.D., Lan J., Huang G., Varin E., Lincet H., Poulain L., Icard P. Citrate induces apoptotic cell death: a promising way for treating gastric carcinoma?. Anticancer Res. 2011, 31:797-805.
50. Zhang X., Varin E., Allouche S., Lu Y., Poulain L., Icard P. Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin. Anticancer Res. 2009, 29:1249-1254.
51. Wang Q., Beaumont K.A., Otte N.J., Font J., Bailey C.G., Van G.M., Sharp D.M., Tiffen J.C., Ryan R.M., Jormakka M., Haass N.K., Rasko J.E., Holst J. Targeting glutamine transport to suppress melanoma cell growth. Int. J. Cancer 2014, 10.
52. McGivan J.D., Bungard C.I. The transport of glutamine into mammalian cells. Front. Biosci. 2007, 12:874-882.
53. Deberardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., Thompson C.B. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19345-19350.
54. Le A., Lane A.N., Hamaker M., Bose S., Gouw A., Barbi J., Tsukamoto T., Rojas C.J., Slusher B.S., Zhang H., Zimmerman L.J., Liebler D.C., Slebos R.J., Lorkiewicz P.K., Higashi R.M., Fan T.W., Dang C.V. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012, 15:110-121.
55. Brand A., Engelmann J., Leibfritz D. A 13C NMR study on fluxes into the TCA cycle of neuronal and glial tumor cell lines and primary cells. Biochimie 1992, 74:941-948.
56. Liu K.J., Kleps R., Henderson T., Nyhus L. 13C NMR study of hepatic pyruvate carboxylase activity in tumor rats. Biochem. Biophys. Res. Commun. 1991, 179:366-371.
57. Catalina-Rodriguez O., Kolukula V.K., Tomita Y., Preet A., Palmieri F., Wellstein A., Byers S., Giaccia A.J., Glasgow E., Albanese C., Avantaggiati M.L. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget 2012, 3:1220-1235.
58. Drapier J.C. Interplay between NO and [Fe-S] clusters: relevance to biological systems. Methods 1997, 11:319-329.
59. Tortora V., Quijano C., Freeman B., Radi R., Castro L. Mitochondrial aconitase reaction with nitric oxide, S-nitrosoglutathione, and peroxynitrite: mechanisms and relative contributions to aconitase inactivation. Free Radic. Biol. Med. 2007, 42:1075-1088.
60. Gardner P.R., Nguyen D.D., White C.W. Aconitase is a sensitive and critical target of oxygen poisoning in cultured mammalian cells and in rat lungs. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12248-12252.
61. Jiang H., De R.M., Verovski V.N., Sonveaux P., Jordan B.F., Law K., Monsaert C., Van den Berge D.L., Verellen D., Feron O., Gallez B., Storme G.A. Activated macrophages as a novel determinant of tumor cell radioresponse: the role of nitric oxide-mediated inhibition of cellular respiration and oxygen sparing. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76:1520-1527.
62. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
63. Zaidi N., Swinnen J.V., Smans K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res. 2012, 72:3709-3714.
64. Beckner M.E., Fellows-Mayle W., Zhang Z., Agostino N.R., Kant J.A., Day B.W., Pollack I.F. Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int. J. Cancer 2010, 126:2282-2295.
65. Zhou Y., Bollu L.R., Tozzi F., Ye X., Bhattacharya R., Gao G., Dupre E., Xia L., Lu J., Fan F., Bellister S., Ellis L.M., Weihua Z. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Mol. Cancer Ther. 2013, 12:2782-2791.
66. Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., Schmidt K., Willson J.K., Markowitz S., Zhou S., Diaz L.A., Velculescu V.E., Lengauer C., Kinzler K.W., Vogelstein B., Papadopoulos N. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
67. Bello-Fernandez C., Packham G., Cleveland J.L. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:7804-7808.
68. Mandal S., Mandal A., Johansson H.E., Orjalo A.V., Park M.H. Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2169-2174.
69. Keith B., Johnson R.S., Simon M.C. HIF1? and HIF2?: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2011, 12:9-22.
70. Lim J.H., Lee Y.M., Chun Y.S., Chen J., Kim J.E., Park J.W. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol. Cell 2010, 38:864-878.
71. Israel M., Schwartz L. On the metabolic origin of cancer: substances that target tumor. Biomed. Res. 2011, 22:130-164.
72. Luo J., Li Y.N., Wang F., Zhang W.M., Geng X. S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. Int. J. Biol. Sci. 2010, 6:784-795.
73. Lu S.C., Mato J.M. S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J. Gastroenterol. Hepatol. 2008, 23(Suppl. 1):S73-S77.
74. Lu S.C. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 1999, 13:1169-1183.
75. Delage B., Fennell D.A., Nicholson L., McNeish I., Lemoine N.R., Crook T., Szlosarek P.W. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int. J. Cancer 2010, 126:2762-2772.
76. Wheatley D.N., Kilfeather R., Stitt A., Campbell E. Integrity and stability of the citrulline-arginine pathway in normal and tumour cell lines. Cancer Lett. 2005, 227:141-152.
77. Lepleux C., Abeilard-Lemoisson E., Duval M., Icard P., Lincet H. siPGK1 sensitizes chemoresistant human ovarian cancer cell lines to cisplatin. Anticancer Res. 2012, 32:4277-4286.
78. Yoshii Y., Furukawa T., Yoshii H., Mori T., Kiyono Y., Waki A., Kobayashi M., Tsujikawa T., Kudo T., Okazawa H., Yonekura Y., Fujibayashi Y. Cytosolic acetyl-CoA synthetase affected tumor cell survival under hypoxia: the possible function in tumor acetyl-CoA/acetate metabolism. Cancer Sci. 2009, 100:821-827.
79. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nunez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 16:3-11.
80. Leist M., Single B., Castoldi A.F., Kuhnle S., Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. 1997, 185:1481-1486.
81. Lelli J.L., Becks L.L., Dabrowska M.I., Hinshaw D.B. ATP converts necrosis to apoptosis in oxidant-injured endothelial cells. Free Radic. Biol. Med. 1998, 25:694-702.
82. Dhup S., Dadhich R.K., Porporato P.E., Sonveaux P. Multiple biological activities of lactic Acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr. Pharm. Des. 2012, 18:1319-1330.
83. Icard P., Lincet H. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim. Biophys. Acta 2012, 1826:423-433.
84. Mullen A.R., Wheaton W.W., Jin E.S., Chen P.H., Sullivan L.B., Cheng T., Yang Y., Linehan W.M., Chandel N.S., Deberardinis R.J. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012, 481:385-388.
85. Lin C.C., Cheng T.L., Tsai W.H., Tsai H.J., Hu K.H., Chang H.C., Yeh C.W., Chen Y.C., Liao C.C., Chang W.T. Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy. Sci. Rep. 2012, 2:785. (Epub@2012 Nov 8. 785). 10.1038/srep00785.
86. Cairns R.A., Mak T.W. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013, 3:730-741.
87. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Wards P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
88. Losman J.A., Looper R.E., Koivunen P., Lee S., Schneider R.K., McMahon C., Cowley G.S., Root D.E., Ebert B.L., Kaelin W.G. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625.
89. Bilton R.L., Booker G.W. The subtle side to hypoxia inducible factor (HIFalpha) regulation. Eur. J. Biochem. 2003, 270:791-798.
90. Mujoo K., Sharin V.G., Martin E., Choi B.K., Sloan C., Nikonoff L.E., Kots A.Y., Murad F. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation. Nitric Oxide 2010, 22:43-50.
91. Muntane J., la Mata M.D. Nitric oxide and cancer. World J. Hepatol. 2010, 2:337-344.
92. Semenza G.L. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:347-353. (Epub@2011 Jul 22. 347-353). 10.1101/sqb.2011.76.010678.
93. Prunotto M., Compagnone A., Bruschi M., Candiano G., Colombatto S., Bandino A., Petretto A., Moll S., Bochaton-Piallat M.L., Gabbiani G., Dimuccio V., Parola M., Citti L., Ghiggeri G. Endocellular polyamine availability modulates epithelial-to-mesenchymal transition and unfolded protein response in MDCK cells. Lab Invest. 2010, 90:929-939.
94. Soda K. The mechanisms by which polyamines accelerate tumor spread. J. Exp. Clin. Cancer Res. 2011, 30:95.
95. Gruning N.M., Lehrach H., Ralser M. Regulatory crosstalk of the metabolic network. Trends Biochem. Sci. 2010, 35:220-227.
96. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8:193-204.
97. Mazurek S., Eigenbrodt E. The tumor metabolome. Anticancer Res. 2003, 23:1149-1154.
98. Tong W.H., Rouault T.A. Metabolic regulation of citrate and iron by aconitases: role of iron-sulfur cluster biogenesis. Biometals 2007, 3:549-564.
99. Jiang B.H., Semenza G.L., Bauer C., Marti H.H. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol. 1996, 271:C1172-C1180.
100. Simon M.C., Liu L., Barnhart B.C., Young R.M. Hypoxia-induced signaling in the cardiovascular system. Annu. Rev. Physiol. 2008, 70:51-71.
101. Choudhari S.K., Chaudhary M., Bagde S., Gadbail A.R., Joshi V. Nitric oxide and cancer: a review. World J. Surg. Oncol. 2013, 11:118.
102. Ying L., Hofseth L.J. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res. 2007, 67:1407-1410.
103. Sonveaux P., Copetti T., De Saedeleer C.J., Vegran F., Verrax J., Kennedy K.M., Moon E.J., Dhup S., Danhier P., Frerart F., Gallez B., Ribeiro A., Michiels C., Dewhirst M.W., Feron O. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One 2012, 7:e33418.
104. De Saedeleer C.J., Copetti T., Porporato P.E., Verrax J., Feron O., Sonveaux P. Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells. PLoS One 2012, 7:e46571.
105. Leite T.C., Coelho R.G., Da S.D., Coelho W.S., Marinho-Carvalho M.M., Sola-Penna M. Lactate downregulates the glycolytic enzymes hexokinase and phosphofructokinase in diverse tissues from mice. FEBS Lett. 2011, 585:92-98.
106. Semenza G.L. Tumor metabolism: cancer cells give and take lactate. J. Clin. Invest. 2008, 118:3835-3837.
107. Sonveaux P., Vegran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., De Saedeleer C.J., Kennedy K.M., Diepart C., Jordan B.F., Kelley M.J., Gallez B., Wahl M.L., Feron O., Dewhirst M.W. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 2008, 118:3930-3942.
108. Galli M., Van G.F., Rongvaux A., Andris F., Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res. 2010, 70:8-11.
109. Hashimoto T., Hussien R., Oommen S., Gohil K., Brooks G.A. Lactate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis. FASEB J. 2007, 21:2602-2612.
110. Ferreira L.M.R. Cancer metabolism: the Warburg effect today. Exp. Mol. Pathol. 2010, 89:372-380.
111. Weinhouse S. The Warburg hypothesis fifty years later. Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin Oncol. 1976, 87:115-126.
112. Wenner C.E., Denn C.S., Weinhouse S. A study of glucose oxidation in whole tissue homogenates. J. Biol. Chem. 1953, 205:409-422.
113. Anso E., Mullen A.R., Felsher D.W., Mates J.M., Deberardinis R.J., Chandel N.S. Metabolic changes in cancer cells upon suppression of MYC. Cancer Metab. 2013, 1:7-1.
114. Sullivan L.B., Martinez-Garcia E., Nguyen H., Mullen A.R., Dufour E., Sudarshan S., Licht J.D., Deberardinis R.J., Chandel N.S. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol. Cell 2013, 51:236-248.
115. Vaughn A.E., Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat. Cell Biol. 2008, 10:1477-1483.
116. Ko M.S., Jung J.Y., Shin I.S., Choi E.W., Kim J.H., Kang S.K., Ra J.C. Effects of expanded human adipose tissue-derived mesenchymal stem cells on the viability of cryopreserved fat grafts in the nude mouse. Int. J. Med. Sci. 2011, 8:231-238.
117. Pavlides S., Tsirigos A., Migneco G., Whitaker-Menezes D., Chiavarina B., Flomenberg N., Frank P.G., Casimiro M.C., Wang C., Pestell R.G., Martinez-Outschoorn U.E., Howell A., Sotgia F., Lisanti M.P. The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010, 9:3485-3505.
118. Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., Romero I.L., Carey M.S., Mills G.B., Hotamisligil G.S., Yamada S.D., Peter M.E., Gwin K., Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 2011, 17:1498-1503.
119. Agustsson T., Ryden M., Hoffstedt J., van H., Dicker V.A., Laurencikiene J., Isaksson B., Permert J., Arner P. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007, 67:5531-5537.
120. Cao D.X., Wu G.H., Yang Z.A., Zhang B., Jiang Y., Han Y.S., He G.D., Zhuang Q.L., Wang Y.F., Huang Z.L., Xi Q.L. Role of beta1-adrenoceptor in increased lipolysis in cancer cachexia. Cancer Sci. 2010, 101:1639-1645.
121. Tisdale M.J. Tumor-host interactions. J. Cell. Biochem. 2004, 93:871-877.
122. Lelbach A., Muzes G., Feher J. Current perspectives of catabolic mediators of cancer cachexia. Med. Sci. Monit. 2007, 13:RA168-RA173.
123. Zhang Y., Daquinag A., Traktuev D.O., Amaya-Manzanares F., Simmons P.J., March K.L., Pasqualini R., Arap W., Kolonin M.G. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res. 2009, 69:5259-5266.
124. Zhang Y., Daquinag A.C., Amaya-Manzanares F., Sirin O., Tseng C., Kolonin M.G. Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. Cancer Res. 2012, 72:5198-5208.
125. Catalan V., Gomez-Ambrosi J., Rodriguez A., Ramirez B., Silva C., Rotellar F., Hernandez-Lizoain J.L., Baixauli J., Valenti V., Pardo F., Salvador J., Fruhbeck G. Up-regulation of the novel proinflammatory adipokines lipocalin-2, chitinase-3 like-1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer. J. Nutr. Biochem. 2011, 22:634-641.
126. Catalan V., Gomez-Ambrosi J., Rodriguez A., Fruhbeck G. Adipose tissue immunity and cancer. Front. Physiol. 2013, 4:275. (275).
127. Seyfried T.N., Flores R.E., Poff A.M., D'Agostino D.P. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 2014, 35:515-527.
128. Veech R.L., Chance B., Kashiwaya Y., Lardy H.A., Cahill G.F. Ketone bodies, potential therapeutic uses. IUBMB Life 2001, 51:241-247.
129. Muppalla J.N., Muddana K., Dorankula S.P., Thokala M.R., Pasupula A.P. Microenvironment-a role in tumour progression and prognosis. J. Clin. Diagn. Res. 2013, 7:2096-2099.
130. Castells M., Thibault B., Delord J.P., Couderc B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int. J. Mol. Sci. 2012, 13:9545-9571.
131. Dirat B., Bochet L., Dabek M., Daviaud D., Dauvillier S., Majed B., Wang Y.Y., Meulle A., Salles B., Le G.S., Garrido I., Escourrou G., Valet P., Muller C. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011, 71:2455-2465.
132. Costa A., Scholer-Dahirel A., Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin. Cancer Biol. 2014, 10.
133. Martinez-Outschoorn U.E., Trimmer C., Lin Z., Whitaker-Menezes D., Chiavarina B., Zhou J., Wang C., Pavlides S., Martinez-Cantarin M.P., Capozza F., Witkiewicz A.K., Flomenberg N., Howell A., Pestell R.G., Caro J., Lisanti M.P., Sotgia F. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 2010, 9:3515-3533.
134. Pavlides S., Tsirigos A., Vera I., Flomenberg N., Frank P.G., Casimiro M.C., Wang C., Fortina P., Addya S., Pestell R.G., Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse Warburg effect": a transcriptional informatics analysis with validation. Cell Cycle 2010, 9:2201-2219.
135. Ayala G., Morello M., Frolov A., You S., Li R., Rosati F., Bartolucci G., Danza G., Adam R.M., Thompson T.C., Lisanti M.P., Freeman M.R., Di V.D. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J. Pathol. 2013, 231:77-87.
136. Koo J.S., Park S., Kim S.I., Lee S., Park B.W. The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol. 2011, 32:787-799.
137. Qian N., Ueno T., Kawaguchi-Sakita N., Kawashima M., Yoshida N., Mikami Y., Wakasa T., Shintaku M., Tsuyuki S., Inamoto T., Toi M. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci. 2011, 102:1590-1596.
138. Witkiewicz A.K., Dasgupta A., Nguyen K.H., Liu C., Kovatich A.J., Schwartz G.F., Pestell R.G., Sotgia F., Rui H., Lisanti M.P. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol. Ther. 2009, 8:1071-1079.
139. Furuta S., Ghajar C.M., Bissell M.J. Caveolin-1: would-be Achilles' heel of tumor microenvironment?. Cell Cycle 2011, 10:3431.
140. Mathupala S.P., Ko Y.H., Pedersen P.L. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim. Biophys. Acta 2010, 1797:1225-1230.
141. Lisanti M.P., Martinez-Outschoorn U.E., Chiavarina B., Pavlides S., Whitaker-Menezes D., Tsirigos A., Witkiewicz A., Lin Z., Balliet R., Howell A., Sotgia F. Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol. Ther. 2010, 10:537-542.
142. Martinez-Outschoorn U.E., Lisanti M.P., Sotgia F. Catabolic cancer-associated fibroblasts (CAFs) transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 2014, 10.
143. Egeblad M., Rasch M.G., Weaver V.M. Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell Biol. 2010, 22:697-706.
144. Misra A., Pandey C., Sze S.K., Thanabalu T. Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT). PLoS One 2012, 7:e49766.
145. Lester R.D., Jo M., Montel V., Takimoto S., Gonias S.L. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J. Cell Biol. 2007, 178:425-436.
146. Erler J.T., Giaccia A.J. Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res. 2006, 66:10238-10241.
147. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
148. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., Chilvers E.R., Dransfield I., Donnelly S.C., Strieter R., Haslett C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999, 5:662-668.
149. Welter M., Rieger H. Interstitial fluid flow and drug delivery in vascularized tumors: a computational model. PLoS One 2013, 8:e70395.
150. Wu M., Frieboes H.B., McDougall S.R., Chaplain M.A., Cristini V., Lowengrub J. The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. J. Theor. Biol. 2013, 320:131-151. (Epub@2012 Dec 7. 131-151). 10.1016/j.jtbi.2012.11.031.
151. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
152. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., Reinhart-King C.A., Margulies S.S., Dembo M., Boettiger D., Hammer D.A., Weaver V.M. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
153. Eng C.H., Yu K., Lucas J., White E., Abraham R.T. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci. Signal. 2010, 3:ra31.
154. Fiaschi T., Giannoni E., Taddei M.L., Cirri P., Marini A., Pintus G., Nativi C., Richichi B., Scozzafava A., Carta F., Torre E., Supuran C.T., Chiarugi P. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013, 12:1791-1801.
155. Scholer-Dahirel A., Costa A., Mechta-Grigoriou F. Control of cancer-associated fibroblast function by oxidative stress: a new piece in the puzzle. Cell Cycle 2013, 12:2169.
156. Toullec A., Gerald D., Despouy G., Bourachot B., Cardon M., Lefort S., Richardson M., Rigaill G., Parrini M.C., Lucchesi C., Bellanger D., Stern M.H., Dubois T., Sastre-Garau X., Delattre O., Vincent-Salomon A., Mechta-Grigoriou F. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med. 2010, 2:211-230.
157. Comito G., Calvani M., Giannoni E., Bianchini F., Calorini L., Torre E., Migliore C., Giordano S., Chiarugi P. HIF-1alpha stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic. Biol. Med. 2011, 51:893-904.
158. Geerts D., Koster J., Albert D., Koomoa D.L., Feith D.J., Pegg A.E., Volckmann R., Caron H., Versteeg R., Bachmann A.S. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int. J. Cancer 2010, 126:2012-2024.
159. Andres V., Carreras J., Cusso R. Regulation of muscle phosphofructokinase by physiological concentrations of bisphosphorylated hexoses: effect of alkalinization. Biochem. Biophys. Res. Commun. 1990, 172:328-334.
160. Wykoff C.C., Beasley N.J., Watson P.H., Turner K.J., Pastorek J., Sibtain A., Wilson G.D., Turley H., Talks K.L., Maxwell P.H., Pugh C.W., Ratcliffe P.J., Harris A.L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60:7075-7083.
161. Robey I.F., Baggett B.K., Kirkpatrick N.D., Roe D.J., Dosescu J., Sloane B.F., Hashim A.I., Morse D.L., Raghunand N., Gatenby R.A., Gillies R.J. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009, 69:2260-2268.
162. Porporato P.E., Dhup S., Dadhich R.K., Copetti T., Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharmacol. 2011, 2.
163. Gatenby R.A., Gawlinski E.T. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 2003, 63:3847-3854.
164. Benej M., Pastorekova S., Pastorek J. Carbonic anhydrase IX: regulation and role in cancer. Subcell. Biochem. 2014, 75:199-219. (199-219). 10.1007/978-94-007-7359-2_11.
165. Cadwell C., Zambetti G.P. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001, 277:15-30.
166. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54:4855-4878.
167. Stern R., Shuster S., Neudecker B.A., Formby B. Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp. Cell Res. 2002, 276:24-31.
168. Robey R.B., Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 2009, 19:25-31.
169. Hunter A., Hendrikse A., Renan M., Abratt R. Does the tumor microenvironment influence radiation-induced apoptosis?. Apoptosis 2006, 11:1727-1735.
170. Moellering R.E., Black K.C., Krishnamurty C., Baggett B.K., Stafford P., Rain M., Gatenby R.A., Gillies R.J. Acid treatment of melanoma cells selects for invasive phenotypes. Clin. Exp. Metastasis 2008, 25:411-425.
171. Rofstad E.K., Mathiesen B., Kindem K., Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006, 66:6699-6707.
172. Hamilton J.A., Lacey D.C., Turner A., de K.B., Huynh J., Scholz G.M. Hypoxia enhances the proliferative response of macrophages to CSF-1 and their pro-survival response to TNF. PLoS One 2012, 7:e45853.
173. Peyssonnaux C., Cejudo-Martin P., Doedens A., Zinkernagel A.S., Johnson R.S., Nizet V. Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J. Immunol. 2007, 178:7516-7519.
174. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
175. Biswas S.K., Allavena P., Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol. 2013, 35:585-600.
176. Allavena P., Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 2012, 167:195-205.
177. Chang C.I., Zoghi B., Liao J.C., Kuo L. The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: its implications in IL-13-inhibited nitric oxide production. J. Immunol. 2000, 165:2134-2141.
178. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
179. Shaw J.P., Utz P.J., Durand D.B., Toole J.J., Emmel E.A., Crabtree G.R. Identification of a putative regulator of early T cell activation genes. Science 1988, 241:202-205.
180. Oikawa T., Nakamura A., Onishi N., Yamada T., Matsuo K., Saya H. Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion. Cancer Res. 2013, 73:5100-5109.
181. Dietl K., Renner K., Dettmer K., Timischl B., Eberhart K., Dorn C., Hellerbrand C., Kastenberger M., Kunz-Schughart L.A., Oefner P.J., Andreesen R., Gottfried E., Kreutz M.P. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J. Immunol. 2010, 184:1200-1209.
182. Fischer K., Hoffmann P., Voelkl S., Meidenbauer N., Ammer J., Edinger M., Gottfried E., Schwarz S., Rothe G., Hoves S., Renner K., Timischl B., Mackensen A., Kunz-Schughart L., Andreesen R., Krause S.W., Kreutz M. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007, 109:3812-3819.
183. Husain Z., Huang Y., Seth P., Sukhatme V.P. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 2013, 191:1486-1495.
184. Lee R.K., Spielman J., Zhao D.Y., Olsen K.J., Podack E.R. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J. Immunol. 1996, 157:1919-1925.
185. Gocheva V., Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007, 6:60-64.
186. Smith H.A., Kang Y. Acute infection induces a metastatic niche: a double menace for cancer patients. Clin. Cancer Res. 2013, 19:4547-4549.
187. Nakano O., Sato M., Naito Y., Suzuki K., Orikasa S., Aizawa M., Suzuki Y., Shintaku I., Nagura H., Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001, 61:5132-5136.
188. Nelson B.H. The impact of T-cell immunity on ovarian cancer outcomes. Immunol. Rev. 2008, 222:101-116. (101-116). 10.1111/j.1600-065X.2008.00614.x.